AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2020
Aug 10, 2020
30751_dirs_2020-08-10_00693ff8-1653-4fcf-a086-0f27ef18d681.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2020-08-06
Reporting Person: ENRIGHT PATRICK G (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-08-06 | Ordinary Shares | A | 2705 | $0.0 | Acquired | 20368 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-08-06 | Non-Qualified Stock Option (right to buy) | $127.07 | A | 6765 | Acquired | 2030-08-05 | Ordinary Shares (6765) | Direct |
Footnotes
F1: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 30, 2021.
F2: These options are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in full on July 30, 2021.